Glimepiride, a new once-daily sulfonylurea: A double-blind placebo- controlled study of NIDDM patients

Diabetes Care

Volumn 19, Issue 11, 1996, Pages 1194-1199

  Rosenstock, Julio ^a   Samols, Ellis ^b   Muchmore, Douglas B ^c   Schneider, Jill ^d  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SCRIPPS CLINIC   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029904041     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.11.1194     Document Type: Article

References (30)

1. Leclercq-Meyer V, Akkan AG, Marchand J, Malaisse WJ: Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas. Biochem Pharmacol 42:1634-1637, 1991
2. Geisen K: Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung 38:1120-1130, 1988
3. Sato J, Ohsawa I, Oshida Y, Sato Y, Sakamoto N: Effects of glimepiride on in vivo insulin action in normal and diabetic rats. Diabetes Res Clin Pract 22:3-9, 1993
4. Müller G, Wied S: The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adiopocytes in vitro. Diabetes 42:1852-1867, 1993
5. Bähr M, von Holtey M, Muller G, Eckel J: Direct Stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride. Endocrinology 136:2547-2553, 1995
6. Landry DW, Oliver JA: The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89:2071-2074, 1992
7. Ballagi-Pordany G, Nemeth M, Aranyi Z, Kekesi E, Koltai MZ, Papp G, Pogatsa G: Effect of glimepiride on the electrical activity of isolated rabbit muscle. Arzneimittelforschung 42:111-113, 1992
8. Badian M, Korn A, Lehr K-H, Malerczyk V, Waldhäusl W: Determination of the absolute bioavailability of glimepiride (HOE 490), a new sulphonylurea. Int J Clin Pharmacol Ther Taxicol 30:481-482, 1992
9. Turpeinen U, Karjalainen U, Stenman UH: Three assays for glycohemoglobin compared. Clin Chem 41:191-195, 1995
10. Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM: Glycated hemoglobin: methodologies and clinical applications. Clin Chem 32 (Suppl): B64-B70, 1986
11. Mosca A, Carpinelli A, Bonini P: Automated determination of glycated hemoglobins with a new high-performance liquid chromatography analyzer. Clin Chem 32:202-203, 1986
12. Brenna S, Prencipe L, Montalbetti N, Perlangeli V, Palpon R: Assessing the automatic DIAMAT liquid Chromatograph for glycated hemoglobins. Clin Chem 32:896, 1986
13. 1c) determination. Ann Acad Med Singapore 18:357-362, 1989
14. Beischer W: Proinsulin and C-peptide in humans. In Hormones in Normal and Abnormal Human Tissues. Vol. 3. Fotherby K, Pal S, Eds. Berlin, Walter DeGruyter, 1983, p. 1-43
15. Beyer J, Krause U, Cordes U: C-peptide: its biogenesis, structure, determination and clinical significance. Giornale Ital Chem Clin 4 (Suppl. 1):9-22, 1979
16. Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548, 1975
17. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH: Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 26:22-29, 1977
18. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH: Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 55:1278-1283, 1975
19. Heding LG, Rasmussen SM: Human C-peptide in normal and diabetic subjects. Diabetologia 11:201-206, 1975
20. Hales CN, Randle PJ: Immunoassay of insulin antibody precipitate. Biochem J 88:137-146, 1963
21. Morgan CR, Lazarow A: Immunoassay of insulin: two antibody system. Diabetes 12:115-126, 1963
22. Prout J: Radioisotope measurements of insulin. In Nuclear Medicine In Vitro. Rothfeld B, Ed. Philadelphia, Lippincott, 1974, p. 267
23. Livesey JH, Hodgkinson SC, Roud HR, Donald RA: Effect of time, temperature and freezing on the stability of immunoreactive LH, FSH, TSH, growth hormone, prolactin and insulin in plasma. Clin Biochem 13:151-155, 1980
24. Raskin P, Ed: Medical Management of Non-Insulin-Dependent (Type II) Diabetes. 3rd ed. Alexandria, VA, American Diabetes Association, 1994
25. American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 18:1510-1518, 1995
26. Goldberg RB, Holvey SM, Schneider J, the Glimepiride Protocol #201 Study Group: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 19:849-856, 1996
27. American Diabetes Association: Detection and management of lipid disorders in diabetes. Diabetes Care 16 (Suppl. 2): 106-112, 1993
28. Kurtz SMS: Adherence to diabetes regimens: empirical status and clinical applications. Diabetes Educ 16:50-56, 1990
29. Nagasawa M, Smith MC, Barnes JH, Fincham JE: Meta-analysis of correlates of diabetes patients' compliance with prescribed medications. Diabetes Educ 16:192-200, 1990
30. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP: Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 44:540-545, 1988